Evidence map›Paper›PMID 28433079›Full record

ArticleThe Journal of molecular diagnostics : JMD2017

Utilization of Whole-Exome Next-Generation Sequencing Variant Read Frequency for Detection of Lesion-Specific, Somatic Loss of Heterozygosity in a Neurofibromatosis Type 1 Cohort with Tibial Pseudarthrosis.

Rebecca L Margraf, Chad VanSant-Webb, David Sant, John Carey, Heather Hanson, Jacques D'Astous, Dave Viskochil, David A Stevenson, Rong Mao

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Low-pass genome sequencing-based detection of absence of heterozygosity: validation in clinical cytogenetics.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  3. Article
  4. NF1 Somatic Mutation in Dystrophic Scoliosis.Journal of molecular neuroscience : MN · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Rebecca L MargrafARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah. Electronic address: rebecca.margraf@aruplab.com.
Chad VanSant-WebbARUP Laboratories, Salt Lake City, Utah.
David SantMiller School of Medicine, University of Miami, Miami, Florida.
John CareyShriners Hospital for Children Salt Lake City, Salt Lake City, Utah; Division of Medical Genetics, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, Utah.
Heather HansonShriners Hospital for Children Salt Lake City, Salt Lake City, Utah.
Jacques D'AstousShriners Hospital for Children Salt Lake City, Salt Lake City, Utah.
Dave ViskochilShriners Hospital for Children Salt Lake City, Salt Lake City, Utah; Division of Medical Genetics, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, Utah.
David A StevensonDivision of Medical Genetics, Department of Pediatrics, Stanford University, Stanford, California.
Rong MaoARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah; Department of Pathology, School of Medicine, University of Utah, Salt Lake City, Utah.
University of Utah · USShriners Hospitals for Children - Salt Lake City · USARUP Laboratories (United States) · USARUP Laboratories (United States) · USStanford University · USUniversity of Miami · US

Funding

UNIVERSITY OF UTAH CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE-UL1: BPCAUL1RR025764 · NCRR · UNIVERSITY OF UTAH · PI MCCLAIN, DONALD A. · 2008 to 2011
$19.4M
NCRR NIH HHS UL1 RR025764
6 · The paper itself

Abstract

A subset of neurofibromatosis type 1 patients develop tibial dysplasia, which can lead to pseudarthrosis. The tissue from the tibial pseudarthrosis region commonly has a somatic second hit in NF1: single-nucleotide variants, small deletions, or loss of heterozygosity (LOH). We used exome next-generation sequencing (NGS) variant frequency data (allelic imbalance analysis) to detect somatic LOH in pseudarthrosis tissue from three individuals with clinically and diagnostically confirmed neurofibromatosis type 1, and verified the results with microarray. The variant files were parsed and plotted using python scripts, and the NGS variant frequencies between the affected tissue and blood sample were compared. Individuals without somatic single-nucleotide variants or small insertions/deletions were tested for somatic LOH using the NGS variant allele frequencies. One individual's NGS data indicated no LOH in chromosome 17. The other two individuals demonstrated somatic LOH inclusive of NF1: one had an LOH region of approximately one million bases and Contra (NGS copy number program) indicated a somatic deletion and the other individual had LOH for most of chromosome 17q and Contra indicated no copy number change (microarray data verified this sample as copy neutral somatic LOH). Both LOH and copy number variation detected by NGS data correlated with microarray data, demonstrating the somatic LOH second hit can be detected directly from the NGS data.

Indexed as

Allelic ImbalanceDNA Copy Number VariationsExomeFemaleGene FrequencyHigh-Throughput Nucleotide SequencingHumansLoss of HeterozygosityMaleNeurofibromatosis 1Pseudarthrosis

Identifiers

PMID28433079
PMCPMC5417040
OpenAlexW2607152337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.